Mohammad Abbas, Vandana Singh Kushwaha, Kirti Srivastava, Monisha Banerjee
{"title":"Understanding Role of DNA Repair and Cytochrome p-450 Gene Polymorphisms in Cervical Cancer Patient Treated With Concomitant Chemoradiation.","authors":"Mohammad Abbas, Vandana Singh Kushwaha, Kirti Srivastava, Monisha Banerjee","doi":"10.3389/bjbs.2021.10120","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Evidences suggest that single nucleotide polymorphisms (SNPs) can be considered as potential biomarkers for disease progression and therapeutic response in cervical cancer. The present study investigated the association of <i>CYP1A1</i> T>C (rs4646903), <i>CYP1A1</i> A>G (rs1048943), <i>CYP2E1</i> T>A (rs6413432), <i>RAD51</i> G>C (rs1801320), <i>XRCC1</i> G>A (rs25487), <i>XRCC2</i> G>A (rs3218536) and <i>XRCC3</i> C>T (rs861539) polymorphisms with treatment outcome of cisplatin based chemoradiation (CRT). <b>Methods:</b> Total 227 cervical cancer cases, treated with the same chemoradiotherapy regimen were selected for the study. Genotyping analysis was performed by PCR-restriction fragment length polymorphisms (PCR-RFLP). Treatment response was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST). Association of all clinical data (responses, recurrence and survival of patients) and single nucleotide polymorphisms (SNPs) was analysed by using SPSS (version 21.0). <b>Results:</b> Patients with TA/AA genotype of <i>CYP2E1</i> T>A polymorphism showed significantly poor response while those with GC/CC genotype of <i>RAD51</i> G>C showed better response (<i>p</i> = 0.008, <i>p</i> = 0.014 respectively). Death was significantly higher in patients with GG genotypes of <i>RAD51</i> G>C and <i>XRCC1</i> G>A (<i>p</i> = 0.006, <i>p</i> = 0.002 respectively). Women with GC+CC genotype of <i>RAD51</i> G>C and AG+GG of <i>XRCC1</i> showed better survival and also reduced risk of death (HR = 0.489, <i>p</i> = 0.008; HR = 0.484, <i>p</i> = 0.003 respectively). <b>Conclusion:</b> Results suggested that <i>CYP2E1</i> T>A (rs6413432), <i>RAD51</i> G>C (rs1801320), and <i>XRCC1</i> G>A (rs25487) polymorphisms may be used as predictive markers for clinical outcomes in cervical cancer patients undergoing cisplatin based concomitant chemoradiotherapy.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":" ","pages":"10120"},"PeriodicalIF":4.6000,"publicationDate":"2022-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915685/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/bjbs.2021.10120","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 3
Abstract
Background: Evidences suggest that single nucleotide polymorphisms (SNPs) can be considered as potential biomarkers for disease progression and therapeutic response in cervical cancer. The present study investigated the association of CYP1A1 T>C (rs4646903), CYP1A1 A>G (rs1048943), CYP2E1 T>A (rs6413432), RAD51 G>C (rs1801320), XRCC1 G>A (rs25487), XRCC2 G>A (rs3218536) and XRCC3 C>T (rs861539) polymorphisms with treatment outcome of cisplatin based chemoradiation (CRT). Methods: Total 227 cervical cancer cases, treated with the same chemoradiotherapy regimen were selected for the study. Genotyping analysis was performed by PCR-restriction fragment length polymorphisms (PCR-RFLP). Treatment response was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST). Association of all clinical data (responses, recurrence and survival of patients) and single nucleotide polymorphisms (SNPs) was analysed by using SPSS (version 21.0). Results: Patients with TA/AA genotype of CYP2E1 T>A polymorphism showed significantly poor response while those with GC/CC genotype of RAD51 G>C showed better response (p = 0.008, p = 0.014 respectively). Death was significantly higher in patients with GG genotypes of RAD51 G>C and XRCC1 G>A (p = 0.006, p = 0.002 respectively). Women with GC+CC genotype of RAD51 G>C and AG+GG of XRCC1 showed better survival and also reduced risk of death (HR = 0.489, p = 0.008; HR = 0.484, p = 0.003 respectively). Conclusion: Results suggested that CYP2E1 T>A (rs6413432), RAD51 G>C (rs1801320), and XRCC1 G>A (rs25487) polymorphisms may be used as predictive markers for clinical outcomes in cervical cancer patients undergoing cisplatin based concomitant chemoradiotherapy.
期刊介绍:
ACS Applied Bio Materials is an interdisciplinary journal publishing original research covering all aspects of biomaterials and biointerfaces including and beyond the traditional biosensing, biomedical and therapeutic applications.
The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrates knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important bio applications. The journal is specifically interested in work that addresses the relationship between structure and function and assesses the stability and degradation of materials under relevant environmental and biological conditions.